Prognostic Value of the Combination of CEA and Fibrinogen/Albumin Ratio in Resectable Gastric Cancer. 2020

Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
Department of Surgical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

OBJECTIVE To investigate the prognostic value of combined serum carcinoembryonic antigen (CEA) levels and fibrinogen/albumin ratio (FAR) in patients with resectable gastric cancer (GC). BACKGROUND This retrospective study evaluated the CEA, fibrinogen, and albumin levels and other clinicopathological features of GC patients. The prognostic significance of these factors for overall survival (OS) was assessed using Kaplan-Meier curves and univariate and multivariate Cox proportional models. METHODS A total of 267 patients were included. The optimal cutoff values of CEA and FAR were 3.2 ng/mL and 0.086, respectively. Patients were stratified into three groups based on this cutoff value: CEA-FAR=0 (CEA <3.2 ng/mL and FAR <0.086), CEA-FAR=1 (CEA ≥3.2 ng/mL or FAR ≥0.086), and CEA-FAR=2 (CEA ≥3.2 ng/mL and FAR ≥0.086). RESULTS Higher CEA-FAR was strongly associated with age, tumor size, tumor invasion, lymph node status, and TNM stage (all P<0.05). The OS rates differed significantly between these 3 groups (88.9% vs 65.0% vs 46.9%, P<0.001). Multivariate analysis showed that CEA-FAR was an independent prognostic factor for OS (P<0.001). The area under the curve was larger for CEA-FAR than for either CEA or FAR alone (0.683, 0.644, and 0.669, respectively). CONCLUSIONS Preoperative CEA-FAR could be a potential blood marker for predicting tumor progression and the prognosis of GC patients. Patients with a higher CEA-FAR should undergo extensive follow-up.

UI MeSH Term Description Entries

Related Publications

Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
January 2024, Journal of inflammation research,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
January 2022, Journal of Cancer,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
January 2022, Annali italiani di chirurgia,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
January 2010, Hepato-gastroenterology,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
October 2020, Oncology letters,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
November 2018, World journal of gastroenterology,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
January 2020, Gastroenterology research and practice,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
May 2020, BMC cancer,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
September 2015, Medicine,
Junbin Zhang, and Jiayin Ruan, and Weibin Wang, and Yimin Lu, and Haiyong Wang, and Xiongfei Yu, and Haohao Wang, and Lisong Teng
April 2021, Medicine,
Copied contents to your clipboard!